Dr. Meredith Hay is internationally known for her research in brain regulation of blood pressure and the use of the peptide Ang-(1-7) to inhibit brain inflammation and the production of reactive oxygen species. She is the inventor of the method of use for Ang-(1-7) and related peptides as cognitive protectants, as well as the lead inventor for the development of the Ang-(1-7) glycosylated derivatives for treatment of vascular dementia and inflammation-related brain diseases. In 2013, Dr. Hay founded the biotech company, ProNeurogen Inc, to advance these peptides to become new drugs for the treatment of inflammation-related cognitive impairment and chronic pain. Dr. Hay and her colleagues are now in clinical trials to advance these novels peptides to treat vascular dementia and memory loss. Dr. Hay has been funded by the National Institutes of Health for more than 35 years and has extensive experience in successfully leading and building large multi-institutional research programs.